KemPharm, Inc. announced that research assessing the oral and intranasal human abuse potential (HAP) of serdexmethylphenidate (SDX), KemPharm's prodrug of d-methylphenidate (d-MPH), as well as new pharmacokinetic (PK) data for KP415, will be presented in four posters and one oral "data blitz session" at the 2019 Annual Meeting of the American Professional Society for ADHD and Related Disorders (APSARD) being held in Washington, D.C., starting January 18, through January 20, 2020. SDX is the major active pharmaceutical ingredient in KP415 and KP484, KemPharm's co-lead clinical development product candidates intended for the treatment of attention-deficit/hyperactivity disorder (ADHD), as well as KP879, a newly identified product candidate being developed for the treatment of Stimulant Use Disorder (SUD). The first poster, titled, "Single-dose pharmacokinetics of KP415, an investigational product containing the prodrug serdexmethylphenidate (SDX) in children and adolescents with ADHD," was a single-dose, single-period study of orally administered KP415 capsules in children 6-12 years of age and adolescents 13-17 years of age. Consistent with prior studies of methylphenidate products, the study found that systemic dose-normalized exposure to d-MPH following oral administration of KP415 was higher in younger children, which appears to be related to lower d-MPH clearance in subjects with lower body weights. This poster is being presented on January 18, 2020. The second poster, also being presented now, titled, "Dose-proportionality and steady-state pharmacokinetics of KP415, an investigational ADHD product containing serdexmethylphenidate (SDX), a novel prodrug of d-methylphenidate," was a Phase 1, open-label, randomized, single-dose, 3-treatment, 3-period crossover study evaluating the PK's of three clinical doses of KP415 in healthy adults. KP415 produced dose-proportional increases in the rate and extent of d-MPH exposure across a relatively wide range of doses, and steady-state plasma concentrations were achieved prior to the third dose. The third poster, being presented January 19, titled, "Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a novel prodrug of d-Methylphenidate, in Recreational Stimulant Abusers," is also featured as one of eight posters selected to participate in an oral "data blitz session." This was a Phase 1, randomized crossover, double-blind, single-dose, active- and placebo-controlled study that compared the HAP and PK's of intranasally administered (IN) SDX and IN d-MPH HCl in recreational stimulant users with a history of intranasal stimulant use. IN SDX produced lower exposure to d-MPH relative to IN d-MPH HCl, and correspondingly, produced pharmacodynamic effects that were significantly lower than IN d-MPH HCI on multiple abuse-related endpoints, including the primary endpoint of maximal (E(sub)max(/sub)) Drug Liking. Finally, the fourth poster, also being presented on January 19th, is titled "Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin(R)XR and Phentermine in Recreational Stimulant Abusers." This was a Phase 1, randomized crossover, double-blind, single-dose, active- and placebo-controlled study of orally administered SDX in recreational stimulant users. The study found that SDX produced a gradual onset of abuse-related effects and maximal effects which were statistically lower than Focalin XR (Schedule II stimulant) on all abuse-related endpoints and statistically lower than phentermine (Schedule IV stimulant) on a majority of abuse-related endpoints. KemPharm funded the studies which were conducted at various external clinical facilities.